


CLAIMS

1. A compound of formula (I)



5

or a pharmaceutically acceptable salt, solvate or derivative thereof.

2. A pharmaceutical composition comprising the compound according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

10

3. A compound according to claim 1 for use as a medicament.

4. A composition according to claim 2 for use as a medicament.

15

5. A compound according to claim 1 for use as a reverse transcriptase inhibitor or modulator.

6. A composition according to claim 2 for use as a reverse transcriptase inhibitor or modulator.

20

7. A compound according to claim 1 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).


25

8. A composition according to claim 2 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

9. A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound according to claim 1.




10. A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a composition according to claim 2.

5 11. A process for preparing the compound of formula (I)



or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

10 (A) condensing a compound of formulae (II), (VI) or (VII)



15


wherein L<sup>1</sup> and L<sup>2</sup> are leaving groups;

with the compound of formula (V)

20 H<sub>2</sub>NNHCH<sub>2</sub>CH<sub>2</sub>OH (V)

or a salt or hydrate thereof;

(B) alkylating the pyrazole of formula (XIII)



with an alkylating agent of formula (XIV)

5

Lg-CH<sub>2</sub>CH<sub>2</sub>OH (XIV)

or a protected derivative thereof;


(C) deprotecting a protected derivative of the compound of formula (I);

10

and optionally converting the compound of formula (I) prepared by any one of steps (A) to (C) into a pharmaceutically acceptable salt, solvate or derivative thereof.


12. A process according to claim 11 wherein L<sup>1</sup> and L<sup>2</sup> are each independently selected  
15 from -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub> and -N(CH<sub>3</sub>)<sub>2</sub>.

13. A compound of formula (II)




20

14. A compound of formula (VI)



wherein L<sup>1</sup> is a leaving group.


5 15. A compound of formula (VII)



wherein L<sup>2</sup> is a leaving group.


10 16. A compound according to claim 14 or 15 wherein L<sup>1</sup> and L<sup>2</sup> are each independently selected from -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub> and -N(CH<sub>3</sub>)<sub>2</sub>.

17. A compound of formula (VIII)



15


18. A compound of formula (IX)



(IX).

19. A compound of formula (XIII)

5



(XIII)